Cargando…

Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study

BACKGROUND: Incarcerated populations experience an elevated prevalence of opioid use disorder (OUD). Federal correctional institutions in Canada have increasingly treated OUD among correctional populations via opioid agonist treatment (OAT) – an evidence based pharmacotherapy that works to reduce dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russell, Cayley, Nafeh, Frishta, Pang, Michelle, MacDonald, Shanna Farrell, Derkzen, Dena, Rehm, Jürgen, Fischer, Benedikt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897889/ https://www.ncbi.nlm.nih.gov/pubmed/35246083 http://dx.doi.org/10.1186/s12889-022-12685-0

Ejemplares similares

Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada
por: Russell, Cayley, et al.
Publicado: (2022)

A qualitative examination of substance use service needs among people who use drugs (PWUD) with treatment and service experience in Ontario, Canada
por: Russell, Cayley, et al.
Publicado: (2021)

Youth substance use service provider’s perspectives on use and service access in ontario: time to reframe the discourse
por: Ali, Farihah, et al.
Publicado: (2022)

The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data
por: Imtiaz, Sameer, et al.
Publicado: (2021)

Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: A national qualitative assessment in Canada
por: Ali, Farihah, et al.
Publicado: (2021)

Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review
por: Malta, Monica, et al.
Publicado: (2019)

Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021
por: Rosic, Tea, et al.
Publicado: (2023)

Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians
por: Huskamp, Haiden A., et al.
Publicado: (2023)

The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada
por: Franklyn, Alexandra M., et al.
Publicado: (2017)

Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study()
por: Russell, Cayley, et al.
Publicado: (2021)

Corrigendum to “Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study” [Journal of Substance Abuse Treatment 129 (2021) 108374]
por: Russell, Cayley, et al.
Publicado: (2021)

Incarceration status at buprenorphine initiation and OUD treatment outcomes during pregnancy
por: Nguyen, Andrea, et al.
Publicado: (2023)

Reductions in non-medical prescription opioid use among adults in Ontario, Canada: are recent policy interventions working?
por: Fischer, Benedikt, et al.
Publicado: (2013)

Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study
por: Larney, Sarah, et al.
Publicado: (2018)

Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder
por: Thakrar, Ashish P., et al.
Publicado: (2023)

A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD)
por: Khatri, Utsha G., et al.
Publicado: (2022)

Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey
por: Kouyoumdjian, Fiona G., et al.
Publicado: (2018)

Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series
por: Patricelli, Charissa J., et al.
Publicado: (2023)

Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada
por: Martins, Diana, et al.
Publicado: (2022)

Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach()
por: Ettienne, Earl B., et al.
Publicado: (2017)

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study
por: Dobischok, Sophia, et al.
Publicado: (2022)

Measuring the Burden of Opioid-related Mortality in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine
por: Abijo, Tomilowo, et al.
Publicado: (2020)

Evidence of Increased Age and Sex Standardized Death Rates Among Individuals Who Accessed Opioid Agonist Treatment Before the Era of Synthetic Opioids in Ontario, Canada
por: Morin, Kristen A, et al.
Publicado: (2021)

Prevalence of Prenatal Opioid Exposure in Ontario, Canada, 2014-2019
por: Camden, Andi, et al.
Publicado: (2021)

Prevalence of alcohol consumption among clients of opioid agonist treatment (OAT) centers in Golestan province, Iran
por: Noroozi, Alireza, et al.
Publicado: (2023)

The effect of opioid analgesics, benzodiazepines, gabapentinoids, and opioid agonist treatment on mortality risk among opioid-dependent people.
por: Bharat, Chrianna, et al.
Publicado: (2022)

The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario
por: Franklyn, Alexandra M., et al.
Publicado: (2017)

Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study
por: Miller, Wendy A., et al.
Publicado: (2023)

Advancing virtual primary care for people with opioid use disorder (VPC OUD): a mixed-methods study protocol
por: Hedden, Lindsay, et al.
Publicado: (2022)

Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
por: Morin, Kristen A., et al.
Publicado: (2020)

Treatment of prescription opioid disorders in Canada: looking at the ‘other epidemic’?
por: Fischer, Benedikt, et al.
Publicado: (2016)

Characteristics of Opioid-Users Whose Death Was Related to Opioid-Toxicity: A Population-Based Study in Ontario, Canada
por: Madadi, Parvaz, et al.
Publicado: (2013)

Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Comparison of Crude Population-Level Indicators of Opioid Use and Related Harm in New Zealand and Ontario (Canada)
por: Fischer, Benedikt, et al.
Publicado: (2020)

The opioid crisis: past, present and future policy climate in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2017)

Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p25l135epqei16cb4atj0rfvs7